CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 1906-A |

# Specialty Guideline Management Kadcyla (ado-trastuzumab emtansine)

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Kadcyla | ado-trastuzumab emtansine |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-Approved Indications

#### Metastatic Breast Cancer (MBC)

Kadcyla, as a single agent, is indicated for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.

#### Early Breast Cancer (EBC)

Kadcyla, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

### Compendial Uses

* Single-agent therapy for recurrent or stage IV (M1) HER2-positive breast cancer
* Non-small cell lung cancer with HER2 mutations
* HER2-positive recurrent, unresectable or metastatic salivary gland tumors

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of human epidermal growth factor receptor 2 (HER2) status is necessary to initiate the prior authorization review.

## Coverage Criteria

### Breast Cancer

* Authorization of 12 months may be granted for subsequent treatment of HER2-positive metastatic or recurrent breast cancer or for HER2-positive breast cancer with no response to preoperative systemic therapy when used as a single agent.
* Authorization of up to 12 months may be granted for adjuvant treatment of HER2-positive early breast cancer when used as a single agent.
* Authorization of 12 months may be granted for initial treatment of small asymptomatic brain metastases in HER2-positive breast cancer when used as a single agent.

### Non-Small Cell Lung Cancer

Authorization of 12 months may be granted for subsequent treatment of non-small cell lung cancer with HER2 (ERBB2) mutations when all of the following criteria are met:

* The disease is recurrent, advanced or metastatic
* The requested medication will be used as a single agent
* The member has not experienced disease progression on a HER2 targeted drug (e.g., Enhertu, Kadcyla)

### Salivary Gland Tumor

Authorization of 12 months may be granted for treatment of recurrent, unresectable or metastatic HER2-positive salivary gland tumors as a single agent.

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the coverage criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen. Adjuvant treatment of breast cancer will be approved for a total of 12 months of therapy.

## References

1. Kadcyla [package insert]. South San Francisco, CA: Genentech, Inc.; February 2022.
2. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. https://www.nccn.org. Accessed September 3, 2024.
3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Head and Neck Cancers. Version 4.2024. Accessed September 3, 2024. https://www.nccn.org/professionals/physician\_gls/pdf/head-and-neck.pdf.